ReviewChemical reviews2019
Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers.
Review in Chemical reviews, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 501 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
501 citing papers in PubMed, 1,500 citations in OpenAlex.
- Beyond radiotheranostics: how imaging modality defines theranostics.European radiology experimental · 2026Review
- Machine Learning-Based Development of Gadolinium Binding Peptides.NMR in biomedicine · 2026Article
- Early detection of invasive lung cancer and multiorgan metastasis by a collagen-targeted protein MRI contrast agent.Science advances · 2026Article
- Bioresorbable and optically readable triboelectric implants enabled by nanoscale iridophosphors.Nature nanotechnology · 2026Article
- Application of nanotherapy in cardiovascular diseases featuring novel pharmacological mechanisms and drug delivery strategies.Discover nano · 2026Review
- Bypassing Heteronuclear MRI: Metal-Free Organosilicon Nanotracers for Background-Free HotspotAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Tuning Core Fluidity in Emulsion Nanoparticles for Stable and Transition-Metal-Free Responsive 19F MRI Probes.Journal of the American Chemical Society · 2026Article
- Sensitive detection of unopposed estrogen using estrogen receptor functionalized nanoprobes for cancer diagnosis.Discover nano · 2026Review
- Asymmetrically Coordinated Dual-Atom Manganese Contrast Agents Enabling High-Efficiency T1 Enhanced MRI for Precise Tumor Visualization.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- A Modular Core-Shell Nanoparticle Platform for Dual-Modal MRI-Luminescence With High Relaxivity.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Development of Sub-50 nm Core-Shell Silica Nanoparticles With Controlled In Vivo Behavior forAngewandte Chemie (International ed. in English) · 2026Article
- Unmasking Early Renal Fibrosis in Polycystic Kidney Disease Using Noninvasive Precision Molecular MRI of Collagen.bioRxiv : the preprint server for biology · 2026Article
- Slowing Down Water: Enhanced and Cation-responsive MRI Contrast.Angewandte Chemie (International ed. in English) · 2026Article
- Advances in Wearable Bioimaging.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Inner- and Second-Sphere Interactions of Co(II) and Fe(II) Parashift Agents with Lactate, Trifluorolactate, and Fluoride.Inorganic chemistry · 2026Article
- Peptide-Based pH-Responsive MRI-CEST Agents: In Vivo Comparison between a Selected Pentapeptide and the Established Iopamidol Reference in Tumor pH Mapping Ability.Chemical & biomedical imaging · 2026Article
- Designing Water-Soluble Macromolecules for Biomedical Use: PEG Chains versus Amino AcidsA Case Study in MRI Contrast Agents.ACS polymers Au · 2026Article
- Complexes of DOTAM with dInorganic chemistry · 2026Article
- Mapping Therapeutic Regulatory T Cell Fate with MRI: Current Strategies and Translational Outlook.Nanomaterials (Basel, Switzerland) · 2026Review
- Two-step distance tuning of TMaterials today. Bio · 2026Article
441 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Tens of millions of contrast-enhanced magnetic resonance imaging (MRI) exams are performed annually around the world. The contrast agents, which improve diagnostic accuracy, are almost exclusively small, hydrophilic gadolinium(III) based chelates. In recent years concerns have arisen surrounding the long-term safety of these compounds, and this has spurred research into alternatives. There has also been a push to develop new molecularly targeted contrast agents or agents that can sense pathological changes in the local environment. This comprehensive review describes the state of the art of clinically approved contrast agents, their mechanism of action, and factors influencing their safety. From there we describe different mechanisms of generating MR image contrast such as relaxation, chemical exchange saturation transfer, and direct detection and the types of molecules that are effective for these purposes. Next we describe efforts to make safer contrast agents either by increasing relaxivity, increasing resistance to metal ion release, or by moving to gadolinium(III)-free alternatives. Finally we survey approaches to make contrast agents more specific for pathology either by direct biochemical targeting or by the design of responsive or activatable contrast agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.